- Home
- MRVI vs ATXS Comparison
MRVI vs ATXS Comparison
Compare MRVI & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRVI
- ATXS
- Stock Information
- Founded
- MRVI 2014
- ATXS 2008
- Country
- MRVI United States
- ATXS United States
- Employees
- MRVI N/A
- ATXS N/A
- Industry
- MRVI Biotechnology: Pharmaceutical Preparations
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- MRVI Health Care
- ATXS Health Care
- Exchange
- MRVI Nasdaq
- ATXS Nasdaq
- Market Cap
- MRVI 371.8M
- ATXS 401.2M
- IPO Year
- MRVI 2020
- ATXS 2015
- Fundamental
- Price
- MRVI $2.42
- ATXS $6.18
- Analyst Decision
- MRVI Hold
- ATXS Buy
- Analyst Count
- MRVI 10
- ATXS 6
- Target Price
- MRVI $5.84
- ATXS $32.00
- AVG Volume (30 Days)
- MRVI 1.4M
- ATXS 268.2K
- Earning Date
- MRVI 08-11-2025
- ATXS 08-12-2025
- Dividend Yield
- MRVI N/A
- ATXS N/A
- EPS Growth
- MRVI N/A
- ATXS N/A
- EPS
- MRVI N/A
- ATXS N/A
- Revenue
- MRVI $219,830,000.00
- ATXS N/A
- Revenue This Year
- MRVI N/A
- ATXS N/A
- Revenue Next Year
- MRVI $7.23
- ATXS N/A
- P/E Ratio
- MRVI N/A
- ATXS N/A
- Revenue Growth
- MRVI N/A
- ATXS N/A
- 52 Week Low
- MRVI $1.67
- ATXS $3.56
- 52 Week High
- MRVI $9.60
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- MRVI 49.60
- ATXS 43.94
- Support Level
- MRVI $2.28
- ATXS $6.12
- Resistance Level
- MRVI $2.47
- ATXS $6.82
- Average True Range (ATR)
- MRVI 0.14
- ATXS 0.41
- MACD
- MRVI -0.01
- ATXS -0.06
- Stochastic Oscillator
- MRVI 27.45
- ATXS 8.11
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.